Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
30 results about "Amnion-derived Cellular Cytokine Solution" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A topical cellular cytokine solution containing a distinct combination of growth factors and cytokines secreted by and released from amnion-derived multipotent progenitor (AMP) cells, with potential immunomodulating and skin healing activities. The amnion-derived cellular cytokine solution (ACCS) contains near physiological levels of transforming growth factor beta, tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2, as well as the angiogenesis factors platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF) and angiogenin that are normally found in healing wounds. Upon spraying the solution onto affected areas, the cytokines and growth factors in ACCS appear to increase the migration, proliferation and differentiation of both keratinocytes and fibroblasts; enhance the migration and phagocytosis of macrophages in wounds; and increase epithelialization. Together these processes may accelerate skin healing and tissue repair. Also, ACCS may be beneficial in the treatment of radiation burns of the skin.
Methods of treating spinal cord injury and minimizing scarring
ActiveUS20090136457A1Promote functional recoveryPromote healingBiocideNervous disorderProgenitorSecreting cell
The invention is directed to methods of promoting the healing of spinal cord injury. The invention is further directed to methods of minimizing the extent of scarring following spinal cord injury. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), each alone or in combination with each other and / or other agents.
Owner:STEMNION
Methods for treating nervous system inquiry and disease
ActiveUS20080286267A1Promoting neuroprotectionBiocideNervous disorderProgenitorNervous system disease
The invention is directed to methods for treating nervous system injury and disease, in particular traumatic brain injury and degenerative nervous system disease. Such methods utilize novel compositions, including but not limited to trophic factor-secreting extraembryonic cells (herein referred to as TSE cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), each alone or in combination with each other and / or other agents.
Owner:STEMNION
Methods for promoting hair growth
The invention is directed to methods for promoting hair growth. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), cell lysates derived therefrom, and cell products derived therefrom, each alone or in combination.
Owner:STEMNION
Methods related to surgery
ActiveUS20090010899A1Promote healingImproved and accelerated healingBiocideMammal material medical ingredientsProgenitorFistula
The invention is directed to methods related to surgery, for example gastrointestinal surgery. In particular, the invention is methods of treating fistulae, promoting accelerated healing of anastomoses and preventing failure of anastomoses. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), cell lysates derived therefrom, and cell products derived therefrom, each alone or in combination.
Owner:STEMNION
Methods of treating spinal cord injury and minimizing scarring
ActiveUS8475788B2Promote healingMinimize the extent of scarringBiocideNervous disorderProgenitorSecreting cell
Owner:STEMNION
Methods for treating pustular conditions of the skin
InactiveUS20090004161A1Promote wound healingLess scarringCosmetic preparationsOrganic active ingredientsProgenitorPustulosis
The invention is directed to methods for treating pustular conditions of the skin, for example, acne. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), cell lysates derived therefrom, and cell products derived therefrom, each alone or in combination.
Owner:STEMNION
Methods for treating nervous system injury and disease
The invention is directed to methods for treating nervous system injury and disease, in particular traumatic brain injury and degenerative nervous system disease. Such methods utilize novel compositions, including but not limited to trophic factor-secreting extraembryonic cells (herein referred to as TSE cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), each alone or in combination with each other and / or other agents.
Owner:STEMNION
Methods for treating inhalation injury
InactiveUS20120207717A1Promote healingEasy to useBiocidePeptide/protein ingredientsProgenitorInhalation
The invention is directed to methods for treating inhalation injuries. Such methods utilize novel cell compositions such extraembryonic cytokine secreting (ECS) cells and Amnion-derived Multipotent Progenitor (AMP) cells and novel cellular factor-containing solution compositions such as extraembryonic cell-derived cellular cytokine solution, Amnion-derived Cellular Cytokine Solution (ACCS), and physiologic cytokine solution (PCS) compositions. The compositions may be used alone or in combination with each other and / or other agents.
Owner:STEMNION
Methods for Reducing the Extent of Light-induced Tissue Inflammation and Injury
InactiveUS20180271914A1Significant comprehensive benefitsPeptide/protein ingredientsMammal material medical ingredientsAmnion-derived Cellular Cytokine SolutionLight induced
The invention is directed to methods for reducing the extent of light-induced tissue injury. The method comprises applying a therapeutically effective amount of Amnion-derived Cellular Cytokine Solution (ACCS) to the tissue prior to or as soon as possible following exposure to the light. In one particular example, the ACCS is applied within 90 minutes following exposure to the light.
Owner:STEMNION
Wound healing device and method
ActiveUS8318197B2Suture equipmentsPeptide/protein ingredientsWound healingAmnion-derived Cellular Cytokine Solution
Owner:STEMNION
Methods for treating ophthalmic disorders, diseases and injuries
The invention is directed to methods for treating ophthalmic disorders, diseases and injuries. In particular, the invention is directed to treating disorders, diseases and injuries of the cornea and ocular surface. Such methods utilize novel compositions including, but not limited to, trophic factor secreting extraembryonic cells (herein referred to as TSE cells), including, but not limited to, Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as Amnion-derived Cellular Cytokine Solution or ACCS), and Physiologic Cytokine Solution (herein referred to as PCS), each alone or in combination with each other and / or other agents.
Owner:STEMNION
Methods for treating ophthalmic disorders, diseases and injuries
The invention is directed to methods for treating ophthalmic disorders, diseases and injuries. In particular, the invention is directed to treating disorders, diseases and injuries of the cornea and ocular surface. Such methods utilize novel compositions including, but not limited to, trophic factor secreting extraembryonic cells (herein referred to as TSE cells), including, but not limited to, Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as Amnion-derived Cellular Cytokine Solution or ACCS), and Physiologic Cytokine Solution (herein referred to as PCS), each alone or in combination with each other and / or other agents.
Owner:STEMNION
Methods related to surgery
ActiveUS8153430B2Improved and accelerated healingInhibition formationMammal material medical ingredientsTissue cultureProgenitorMedicine
Owner:STEMNION
Methods for treating ocular contusion and blunt injury and traumatic injury to the optic nerve
ActiveUS9636364B2Treat ocular contusion and blunt injuryAmeliorating optic nerve degenerationPowder deliveryPeptide/protein ingredientsProgenitorInjury cause
The invention is directed to methods for treating ocular contusion and blunt injury to the eye and for treating traumatic injury of the optic nerve. The invention is further directed to treating ocular contusion and blunt injury to the eye and for treating traumatic injury of the optic nerve by administering to a subject suffering from such conditions Amnion-derived Cellular Cytokine Solution (ACCS), including immediate-release, targeted-release, and sustained-release (SR) ACCS compositions (referred to herein as “SR-ACCS” compositions) and / or Amnion-derived Multipotent Progenitor (AMP) cell compositions. Such administration includes intranasal administration of ACCS and / or AMP cells.
Owner:STEMNION
Methods for treating dental diseases, disorders, and injuries
ActiveUS8444417B2Prevent diseaseArresting its developmentAntibacterial agentsCosmetic preparationsDiseaseProgenitor
Owner:STEMNION
Immortalized cell compositions and compositions derived therefrom
InactiveUS20150079190A1Low variabilitySimple manufacturing processGenetically modified cellsCulture processProgenitorBiology
Owner:STEMNION
Methods for treating pustular conditions of the skin
ActiveUS20130183387A1Promote healingPromote wound healingOrganic active ingredientsCosmetic preparationsProgenitorPustulosis
The invention is directed to methods for treating pustular conditions of the skin, for example, acne. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), cell lysates derived therefrom, and cell products derived therefrom, each alone or in combination.
Owner:STEMNION
Methods for promoting hair growth
Owner:STEMNION
Methods for treating dental diseases, disorders, and injuries
ActiveUS20120156649A1Prevent diseaseArresting its developmentAntibacterial agentsCosmetic preparationsProgenitorDisease
Methods for preventing, reversing, ameliorating or treating dental diseases, disorders or injuries are provided. In particular, methods for preventing, reversing, ameliorating or treating dental diseases of the gingival (gums) and bone are provided. Such methods utilize novel compositions including, but not limited to, extraembryonic cytokine-secreting cells (herein referred to as ECS cells), including, but not limited to, Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as Amnion-derived Cellular Cytokine Solution or ACCS), and Physiologic Cytokine Solution (herein referred to as PCS), each alone or in combination with each other and / or other agents.
Owner:STEMNION
Methods for reducing and/or preventing excessive cellular apoptosis
InactiveUS20140037591A1Preventing and reducing apoptosis-induced cell deathPrevent and reduce numberBiocidePeptide/protein ingredientsProgenitorApoptosis
The invention is directed to novel methods for reducing the number of apoptotic cell deaths in a population of cells undergoing excessive cellular apoptosis. The invention is also directed to novel methods for preventing apoptotic cell death in a population of cells at risk for developing excessive cellular apoptosis. In particular, the invention is directed to novel methods for reducing or preventing excessive cellular apoptosis comprising exposing cells exhibiting or at risk for developing excessive cellular apoptosis to a novel cellular factor-containing composition called Amnion-derived Cellular Cytokine Solution (referred to herein as ACCS), which is obtained from the culturing of Amnion-derived Multipotent Progenitor (AMP) cells, or AMP cells.
Owner:STEMNION
Immortalized cell compositions and compositions derived therefrom
InactiveUS20120237607A1Eliminates inherent variabilitySimple manufacturing processGenetically modified cellsCulture processProgenitorChemical composition
The invention is directed to immortalized cell compositions and compositions derived therefrom. The invention is further directed to methods of making and using such immortalized cell compositions and compositions derived therefrom. Such immortalized cell compositions include but are not limited to Immortalized Amnion-derived Multipotent Progenitor cells (herein referred to as I-AMP cells) and conditioned media derived therefrom (herein referred to as I-Amnion-derived Cellular Cytokine Solution or I-ACCS).
Owner:STEMNION
Modulating Ischemic Injury
InactiveUS20160000874A1Preventing modulating reducing treating ameliorating ischemic injuryExtension of timePeptide/protein ingredientsAntipyreticIntact tissueActive agent
Owner:STEMNION
Medical device
ActiveUS9220817B2Reducing its effectivenessGood biocompatibilitySurgeryCoatingsProgenitorSecreting cell
Owner:STEMNION
Methods for reducing and/or preventing excessive cellular apoptosis
ActiveUS20150152383A1Reduce in quantityPeptide/protein ingredientsMammal material medical ingredientsProgenitorApoptosis
Owner:STEMNION
Methods for treating dental diseases, disorders and injuries
InactiveUS20130302262A1Prevent diseaseArresting its developmentAntibacterial agentsCosmetic preparationsDiseaseProgenitor
Owner:STEMNION
Methods for treating ocular contusion and blunt injury and traumatic injury to the optic nerve
ActiveUS20150150915A1Treat ocular contusion and blunt injuryAmeliorating optic nerve degenerationBiocidePowder deliveryProgenitorImmediate release
The invention is directed to methods for treating ocular contusion and blunt injury to the eye and for treating traumatic injury of the optic nerve. The invention is further directed to treating ocular contusion and blunt injury to the eye and for treating traumatic injury of the optic nerve by administering to a subject suffering from such conditions Amnion-derived Cellular Cytokine Solution (ACCS), including novel immediate-release, targeted-release, and sustained-release (SR) ACCS compositions (referred to herein as “SR-ACCS” compositions) and / or and Amnion-derived Multipotent Progenitor (AMP) cell compositions. Such administration includes intranasal administration of ACCS and / or AMP cells.
Owner:STEMNION
Methods for Reducing the Extent of Light-induced Tissue Inflammation and Injury
InactiveUS20200147145A1Peptide/protein ingredientsMammal material medical ingredientsBiochemistryAmnion-derived Cellular Cytokine Solution
Owner:STEMNION
Methods for promoting hair growth
The invention is directed to methods for promoting hair growth. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), cell lysates derived therefrom, and cell products derived therefrom, each alone or in combination.
Owner:STEMNION
Medical Device
ActiveUS20140271773A1Reducing its effectivenessGood biocompatibilityPeptide/protein ingredientsSurgeryProgenitorSecreting cell
The invention is directed to an improved medical device. In particular, the invention is directed to an improved medical device having a coating comprising novel cellular factor-containing solution compositions (referred to herein as CFS compositions), such CFS compositions including conditioned medium compositions obtained from culturing extraembryonic cytokine secreting cells (ECS cells), including Amnion-derived Cellular Cytokine Solution (referred to herein as ACCS) obtained from culturing Amnion-derived Multipotent Progenitor (AMP) cells, dispersed in a polymeric coating material.
Owner:STEMNION
Methods related to surgery
InactiveUS20120164115A1Promote healingImproved and accelerated healingBiocidePeptide/protein ingredientsProgenitorFistula
The invention is directed to methods related to surgery, for example gastrointestinal surgery. In particular, the invention is methods of treating fistulae, promoting accelerated healing of anastomoses and preventing failure of anastomoses. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), cell lysates derived therefrom, and cell products derived therefrom, each alone or in combination.
Owner:PALLADINO LINDA O +4
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com